Patient Characteristics and Outcome After Nonmyeloablative Allogeneic Transplant
| No. . | UPN . | Dx . | Age/ Sex . | Transplant Dose/kg . | RBC/Plt Tx . | Days to ANC > 500 . | Discharge Day . | Survival Day . | |
|---|---|---|---|---|---|---|---|---|---|
| CD34 × 106 . | CD3 × 108 . | ||||||||
| 1 | 77 | Mel | 23/M | 13.5 | 2.1 | 1/1 | 11 | 13 | 85: DP |
| 2 | 79 | Mel | 27/M | 7.8 | 4.0 | 2/1 | 9 | NA | 15: DP |
| 3 | 80 | CML (2CP) | 68/M | 12.2 | 3.8 | 0/1 | 15 | 21 | 106: DP |
| 4 | 85 | Mel | 42/F | 9.5 | 5.2 | 0/0 | 9 | 12 | 199: DP |
| 5 | 86 | RCC | 50/M | 9.1 | 2.0 | 1/0 | 11 | 23 | >409: CR |
| 6 | 89 | Mel | 50/F | 5.1 | 1.1 | 2/3 | 10 | NA | 59: TRM |
| 7 | 91 | CML-CP | 56/F | 6.6 | 1.1 | 2/0 | 12 | 21 | >379: CR |
| 8 | 93 | RCC | 46/M | 5.8 | 1.4 | 0/3 | 11 | 13 | >351: CRU |
| 9 | 95 | MDS (RAEBT) | 60/M | 6.8 | 1.8 | 0/0 | 10 | 10 | 205: Bacterial sepsis |
| 10 | 102 | Relapsed NHL | 55/F | 7.5 | 2.7 | 0/0 | 14 | 13 | >220: CR |
| 11 | 107 | MDS (RAEBT) | 58/M | 3.4 | 3.5 | 2/3 | 14 | 20 | 248: DP |
| 12 | 109 | CMML | 56/M | 6.2 | 5.2 | 2/0 | 11 | 21 | >180: CR |
| 13 | 113 | RCC | 48/M | 6.0 | 1.6 | 1/0 | 11 | 1 | >160: PR |
| 14 | 115 | CML-CP | 28/M | 3.7 | 4.6 | 1/0 | 13 | 4 | >159: CR |
| 15 | 118 | EMP | 34/F | 6.5 | 3.3 | 2/0 | 11 | 17 | >121: Relapse |
| No. . | UPN . | Dx . | Age/ Sex . | Transplant Dose/kg . | RBC/Plt Tx . | Days to ANC > 500 . | Discharge Day . | Survival Day . | |
|---|---|---|---|---|---|---|---|---|---|
| CD34 × 106 . | CD3 × 108 . | ||||||||
| 1 | 77 | Mel | 23/M | 13.5 | 2.1 | 1/1 | 11 | 13 | 85: DP |
| 2 | 79 | Mel | 27/M | 7.8 | 4.0 | 2/1 | 9 | NA | 15: DP |
| 3 | 80 | CML (2CP) | 68/M | 12.2 | 3.8 | 0/1 | 15 | 21 | 106: DP |
| 4 | 85 | Mel | 42/F | 9.5 | 5.2 | 0/0 | 9 | 12 | 199: DP |
| 5 | 86 | RCC | 50/M | 9.1 | 2.0 | 1/0 | 11 | 23 | >409: CR |
| 6 | 89 | Mel | 50/F | 5.1 | 1.1 | 2/3 | 10 | NA | 59: TRM |
| 7 | 91 | CML-CP | 56/F | 6.6 | 1.1 | 2/0 | 12 | 21 | >379: CR |
| 8 | 93 | RCC | 46/M | 5.8 | 1.4 | 0/3 | 11 | 13 | >351: CRU |
| 9 | 95 | MDS (RAEBT) | 60/M | 6.8 | 1.8 | 0/0 | 10 | 10 | 205: Bacterial sepsis |
| 10 | 102 | Relapsed NHL | 55/F | 7.5 | 2.7 | 0/0 | 14 | 13 | >220: CR |
| 11 | 107 | MDS (RAEBT) | 58/M | 3.4 | 3.5 | 2/3 | 14 | 20 | 248: DP |
| 12 | 109 | CMML | 56/M | 6.2 | 5.2 | 2/0 | 11 | 21 | >180: CR |
| 13 | 113 | RCC | 48/M | 6.0 | 1.6 | 1/0 | 11 | 1 | >160: PR |
| 14 | 115 | CML-CP | 28/M | 3.7 | 4.6 | 1/0 | 13 | 4 | >159: CR |
| 15 | 118 | EMP | 34/F | 6.5 | 3.3 | 2/0 | 11 | 17 | >121: Relapse |
Abbreviations: RCC, renal cell carcinoma (metastatic); Mel, melanoma (metastatic); CML-CP, chronic myelogenous leukemia in chronic phase; MDS, myelodysplastic syndrome; RAEBT, refractory anemia with excess blasts; NHL, diffuse large cell non-Hodgkin’s lymphoma (stage IV); CMML, chronic myelomonocytic leukemia; EMP, extramedullary plasmacytoma (multiple, unresectable, and treatment refractory); DP, disease progression; CR, complete response; CRU, complete response unsure; TRM, treatment-related mortality; PR, partial response.